WO2014106772A3 - Фармацевтическая композиция для лечения гиперплазии предстательной железы - Google Patents

Фармацевтическая композиция для лечения гиперплазии предстательной железы Download PDF

Info

Publication number
WO2014106772A3
WO2014106772A3 PCT/IB2013/003050 IB2013003050W WO2014106772A3 WO 2014106772 A3 WO2014106772 A3 WO 2014106772A3 IB 2013003050 W IB2013003050 W IB 2013003050W WO 2014106772 A3 WO2014106772 A3 WO 2014106772A3
Authority
WO
WIPO (PCT)
Prior art keywords
glu
asp
prostatic hyperplasia
pharmaceutical composition
treatment
Prior art date
Application number
PCT/IB2013/003050
Other languages
English (en)
French (fr)
Other versions
WO2014106772A2 (ru
Inventor
Михаил Владимирович ОВЧИННИКОВ
Евгений Александрович ЧЕРТОРИЖСКИЙ
Пётр Александрович БЕЛЫЙ
Original Assignee
Замертон Холдингс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Замертон Холдингс Лимитед filed Critical Замертон Холдингс Лимитед
Priority to EP13866485.9A priority Critical patent/EP2921176A2/en
Publication of WO2014106772A2 publication Critical patent/WO2014106772A2/ru
Publication of WO2014106772A3 publication Critical patent/WO2014106772A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к медицине и касается фармацевтической композиции, содержащей пептиды Ala-Asp-Glu, Lys-Asp-Glu и Asp-Glu-Gly, активной относительно доброкачественной гиперплазии предстательной железы, её применению для лечения доброкачественной гиперплазии предстательной железы, и способу лечения доброкачественной гиперплазии предстательной железы Композиция обладает выраженным эффектом, который значительно превосходит а 1-адреноб локаторы и ингибиторы 5 α-редуктазы. Обнаруженный эффект позволяет использовать фармацевтическую композицию, содержащую пептиды Ala-Asp-Glu, Lys-Asp-Glu и Asp-Glu-Gly для лечения доброкачественной гиперплазии предстательной железы.
PCT/IB2013/003050 2012-11-15 2013-11-14 Фармацевтическая композиция для лечения гиперплазии предстательной железы, её применение для лечения гиперплазии предстательной железы и способ лечения гиперплазии предстательной железы WO2014106772A2 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13866485.9A EP2921176A2 (en) 2012-11-15 2013-11-14 Pharmaceutical composition for treatment of prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201201417A EA201201417A1 (ru) 2012-11-15 2012-11-15 Фармацевтическая композиция для лечения гиперплазии предстательной железы, её применение для лечения гиперплазии предстательной железы и способ лечения гиперплазии предстательной железы
EA201201417 2012-11-15

Publications (2)

Publication Number Publication Date
WO2014106772A2 WO2014106772A2 (ru) 2014-07-10
WO2014106772A3 true WO2014106772A3 (ru) 2014-11-27

Family

ID=49232863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003050 WO2014106772A2 (ru) 2012-11-15 2013-11-14 Фармацевтическая композиция для лечения гиперплазии предстательной железы, её применение для лечения гиперплазии предстательной железы и способ лечения гиперплазии предстательной железы

Country Status (3)

Country Link
EP (1) EP2921176A2 (ru)
EA (1) EA201201417A1 (ru)
WO (1) WO2014106772A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025549B1 (ru) * 2014-09-09 2017-01-30 Замертон Холдингс Лимитед Композиция и средства для профилактики и лечения заболеваний суставов и позвоночника и способы их применения
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190226A1 (en) * 2003-06-10 2007-08-16 Kyowa Hakko Food Specialites Co., Ltd. Seasoning
WO2007139433A1 (en) * 2006-05-30 2007-12-06 Obschestvo S Ogranichennoi Otvetstvennostyu "Sia Peptides" Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
DE102008014882A1 (de) * 2008-03-17 2009-09-24 Friedrich-Schiller-Universität Jena Neuartige Fusionspeptide, bestehend aus einer Kopplung einer Silencingdomäne mit einem Peptidaptamer, zur Hemmung des Androgenrezeptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62941C2 (en) * 1996-09-12 2004-01-15 A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with inhibitors or blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with inhibitors or blocking agents.
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190226A1 (en) * 2003-06-10 2007-08-16 Kyowa Hakko Food Specialites Co., Ltd. Seasoning
WO2007139433A1 (en) * 2006-05-30 2007-12-06 Obschestvo S Ogranichennoi Otvetstvennostyu "Sia Peptides" Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
DE102008014882A1 (de) * 2008-03-17 2009-09-24 Friedrich-Schiller-Universität Jena Neuartige Fusionspeptide, bestehend aus einer Kopplung einer Silencingdomäne mit einem Peptidaptamer, zur Hemmung des Androgenrezeptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAEHASHI K ET AL: "ISOLATION OF PEPTIDES FROM AN ENZYMATIC HYDROLYSATE OF FOOD PROTEINS AND CHARACTERIZATION OF THEIR TASTE PROPERTIES", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, TOKYO, JAPAN, vol. 63, no. 3, 1 January 1999 (1999-01-01), pages 555 - 559, XP009050532, ISSN: 0916-8451, DOI: 10.1271/BBB.63.555 *

Also Published As

Publication number Publication date
EP2921176A2 (en) 2015-09-23
WO2014106772A2 (ru) 2014-07-10
EA018614B1 (ru) 2013-09-30
EA201201417A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2022000270A (es) Dispositivo para el suministro de una composicion para el cuidado de la piel.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2020009256A (es) Compuestos para el tratamiento de cancer.
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MX2016001865A (es) Inhibidores biciclicos.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2017011018A (es) Inhibicion de la actividad de olig2.
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
ZA201901367B (en) Inhibition of olig2 activity
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
WO2015156674A3 (en) Method for treating cancer
IL254899A0 (en) Preparations and methods for treating and/or preventing necrosis of a cell or tissue specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes
WO2014106772A3 (ru) Фармацевтическая композиция для лечения гиперплазии предстательной железы
WO2011116351A3 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013866485

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13866485

Country of ref document: EP

Kind code of ref document: A2